Neurocrine Biosciences, Inc. (NB3.F)

131,05 -0,45 (-0,34%) Ab 08:00AM CEST. Markt geöffnet.

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 1.448

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Kevin C. Gorman Ph.D.	CEO & Director	1,91M	N/A	1958
Mr. Matthew C. Abernethy	Chief Financial Officer	983,3k	N/A	1980
Dr. Jude Onyia Ph.D.	Chief Scientific Officer	1,14M	N/A	1964
Mr. Kyle W. Gano Ph.D.	Chief Business Development & Strategy Officer	920,4k	N/A	1973
Dr. Eiry Wyn Roberts M.D.	Chief Medical Officer	1,04M	3,86M	1964
Jane Sorensen	Head of Investor Relations	N/A	N/A	N/A
Mr. Darin M. Lippoldt Esq.	Chief Legal Officer & Corporate Secretary	856,16k	2,77M	1966
Ms. Julie S. Cooke	Chief Human Resources Officer	N/A	N/A	1966
Mr. Eric S. Benevich	Chief Commercial Officer	748,31k	274,71k	1965
Mr. David Warren Boyer	Chief Corporate Affairs Officer	N/A	N/A	1980

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Corporate Governance

Neurocrine Biosciences, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 2. Die grundlegenden Scores sind Audit: 3, Vorstand: 1, Shareholderrechte: 3, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.